Josiah D. Land, PharmD, BCOP 
 Clinical Pharmacy Specialist
 Thoracic Medical Oncology Team
 Memorial Sloan Kettering Cancer Center
 New York, New York

Originally from Lake Charles, Louisiana, Dr. Josiah Land received his BS in Biology from McNeese State University in Lake Charles and his PharmD from the University of Louisiana at Monroe in Monroe, LA. After pharmacy school, he completed a PGY1 Pharmacy Residency at The University of Texas MD Anderson Cancer Center in Houston, TX followed by a PGY2 Oncology Pharmacy Residency at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Land is currently the Clinical Pharmacy Specialist for the Thoracic Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York, NY. He is a Board Certified Oncology Pharmacist (BCOP) through the Board of Pharmacy Specialties (BPS).

 Val Adams, PharmD, FCCP, BCOP
 University of Kentucky College of Pharmacy
 Markey Cancer Center
 Lexington, Kentucky

Dr. Val Adams is an Associate Professor in the Department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. He co-chairs the protocol review and monitoring committee for the NCI Designated Markey Cancer Center. As the Director of the hematology/oncology residency program, he has trained 40 PGY2 oncology residents and maintains an active research program. He has trained two post-doctoral fellows, been the thesis advisor for four masters students, and served on 20 PhD dissertation student committees serving as advisor or co-advisor for 7 of them. He received his BS in Pharmacy from the University of Utah and received his Doctor of Pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations.

A commercial interest is defined as any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Planner
Joan B. Fowler, PharmD, BCPS—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters
Josiah D. Land, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Val R. Adams, PharmD, FCCP, BCOP—has disclosed that he is a consultant for Amgen.

Content Reviewers
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Joshua Bauml, MD—has disclosed that he is a consultant for  AstraZeneca, BMS, Celgene, Merck, Janssen, Genentech, Guardant Health, Boehringer Ingelheim, Takeda, Regeneron, Ayala, and Inivata. He receives grant/research support from Merck, Incyte, Carevive Systems, Novartis, Bayer, Janssen, Astra Zeneca, Takeda, Amgen.